Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study

Abstract Progression of disease within 24 months (POD24) from diagnosis in marginal zone lymphoma (MZL) was shown to portend poor outcomes in prior studies. However, many patients with MZL do not require immediate therapy, and the time from diagnosis-to-treatment interval can be highly variable with...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Narendranath Epperla, Rina Li Welkie, Pallawi Torka, Geoffrey Shouse, Reem Karmali, Lauren Shea, Andrea Anampa-Guzmán, Timothy S. Oh, Heather Reaves, Montreh Tavakkoli, Kathryn Lindsey, Irl Brian Greenwell, Emily Hansinger, Colin Thomas, Sayan Mullick Chowdhury, Kaitlin Annunzio, Beth Christian, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Nancy L. Bartlett, Alex F. Herrera, Natalie S. Grover, Adam J. Olszewski
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2023-05-01
coleção:	Journal of Hematology & Oncology
Assuntos:	POD24 Non-POD24 Marginal zone lymphoma Overall survival
Acesso em linha:	https://doi.org/10.1186/s13045-023-01448-y
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!